Fairman Group
ABBV icon

Fairman Group’s AbbVie ABBV Stock Holding History

Fairman Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$258K Buy
987
+1
+0.1% +$256 0.18% 56
2026
Q2 		$248K Buy
986
+925
+1,516% +$199K 0.2% 55
2026
Q1 		$13.3K Hold
61
– – 0.01% 144
2025
Q4 		$13.8K Buy
61
+1
+2% +$228 0.01% 141
2025
Q3 		$13.9K Hold
60
– – 0.01% 150
2025
Q2 		$11.1K Buy
60
+1
+2% +$186 0.01% 155
2025
Q1 		$10.4K Sell
59
-9
-13% -$1.75K 0.01% 146
2024
Q4 		$12K Sell
68
-9
-12% -$1.66K 0.01% 149
2024
Q3 		$15.2K Hold
77
– – 0.01% 150
2024
Q2 		$13.1K Buy
77
+1
+1% +$166 0.01% 156
2024
Q1 		$13.8K Sell
76
-420
-85% -$72.4K 0.01% 143
2023
Q4 		$76.8K Buy
+496
New +$72.3K 0.07% 85

Other funds holding ABBV

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Fairman Group's ABBV Position: Q3 2026 in Review

Fairman Group increased its AbbVie (ABBV) stake by 0.1% in Q3 2026, buying an estimated $256 and bringing the position to 987 shares worth $258K. The position accounts for 0.18% of the portfolio, ranked #56.

Fairman Group first reported a position in ABBV in Q4 2023 and has held it in 12 quarters since. 2,418 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Fairman Group held 987 shares of AbbVie worth $258K as of Q3 2026.
  • Fairman Group bought 1 AbbVie share in Q3 2026, an estimated $256.
  • AbbVie made up 0.18% of Fairman Group's portfolio in Q3 2026, its #56 holding.
  • Fairman Group first reported a position in AbbVie in Q4 2023 and has held it in 12 quarters since.
  • 2,418 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Fairman Group's 13F filing for Q3 2026, filed 26 Oct 2026.